TEKT5

Across TCGA pan-cancer cohorts, TEKT5 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of TEKT5’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where TEKT5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TEKT5 is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.

LUAD, LIHC, and BRCA are the cancer types where TEKT5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TEKT5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	All	+0.418	<.001	8	view →
LIHC	Male	II,III,IV	+0.651	<.001	7	view →
BRCA	All	III,IV	+0.546	<.001	6	view →
UCEC	All	All	+0.387	<.001	6	view →
KIRC	Male	All	+0.060	.001	4	view →
CHOL	Male	All	+0.216	.049	1	view →
LUSC	Male	III,IV	−0.187	.043	1	view →
KIRP	All	All	+0.095	.024	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

TEKT5–LUAD

Open the LUAD breakdown →